spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focusses on geographic or therapeutic territories.

For further information please contact:

Advertising
David Hirsh 

Editorial
Rema Farhan

 

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for phones and tablets. You can download issues for offline reading, and our archives go as far back as 2008! Download for free on the App Store, GooglePlay, or Amazon.

     


Click here to view the digital version of EBR


 


ebr
 
 
Featured in this issue
peptides and proteins
Generating High-Quality Protein Reagents from Eukaryotic Cells

Cell Culture Considerations

Both Escherichia coli and eukaryotic systems have their pros and cons, yet the former is selected more often due to speed and cost implications. Dr Mark Abbott at Peak Proteins discusses the factors to be considered.


Bioelectronics
Electroceutical Therapy for Chronic Pain

Effective Electroceuticals

Dr Sree Koneru at BioElectronic Corporation and Dr Kenneth McLeod at the State University of New York in Binghamton, outline the benefits of electroceutical treatments for many neurological disorders and compare this to the widely recognised central sensitisation.
  peptides and proteins
Process-Specific Versus Generic Host Cell Protein Impurity Assays

Biologics Process Analysis

Given the rise in therapeutic antibody production, it has become more important than ever to address issues associated with host cell proteins, as detailed by Ken Hoffman, Eric Bishop, Dr Alla Zilberman, and Dr Jared Isaac at Cygnus Technologies.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October


Widgets Magazine
 
Widgets Magazine

Industry Events

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018, Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.
More info >>

 
News and Press Releases

Quanticate Partners with CluePoints to Offer Data Quality Oversight capabilities

Quanticate, a data-focused clinical research organisation (CRO), has announced that it has partnered with CluePoints as part of its new Data Quality Oversight service.
More info >>

air transport logo

 

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement